Imatinib (Mesylate), 25 mg

A research-grade small molecule from STEMCELL Technologies, this compound is supplied as the mesylate salt of imatinib and acts as a first-generation tyrosine kinase inhibitor. It selectively targets certain tyrosine kinases, including ABL, platelet-derived growth factor receptor (PDGFR), and KIT, and is referenced in research on chronic myelogenous leukemia (CML), gastrointestinal stromal tumors, and other cancers. Alternative names listed in the supplier documentation include CGP57148B, Gleevec, Glivec, and STI-571, and the CAS number is 220127-57-1. The molecular formula is C29H31N7O · CH4SO3, the molecular weight is 589.7 g/mol, the physical form is a crystalline solid, and the stated purity is ≥ 98%.

Reported solubility values are approximately 2 mg/mL in PBS (pH 7.2), approximately 10 mg/mL in DMF, approximately 0.2 mg/mL in EtOH, and approximately 14 mg/mL in DMSO, with supplier-recommended working solubility ceilings of PBS (pH 7.2) ≤ 3.3 mM, DMSO ≤ 20 mM, and absolute ethanol ≤ 330 µM. The product is reported stable at -20°C as supplied and should be protected from prolonged exposure to light. According to the manufacturer's safety documentation, the substance is classified as harmful if swallowed (Acute toxicity, Oral Category 4), and the calculated ATEmix (oral) is 500.00 mg/kg. Published research applications include inhibition of BCR-ABL in CML models, suppression of autonomous erythropoiesis in polycythemia vera primary cell cultures, and modulation of mesenchymal stem cell, osteoblast, and osteoclast behaviour.